2. Search Result
Search Result
Results for "

Domain

" in MedChemExpress (MCE) Product Catalog:

780

Inhibitors & Agonists

5

Screening Libraries

3

Fluorescent Dye

5

Biochemical Assay Reagents

163

Peptides

69

Inhibitory Antibodies

57

Natural
Products

418

Recombinant Proteins

18

Isotope-Labeled Compounds

81

Antibodies

2

Click Chemistry

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151577
    STAT3-SH2 domain inhibitor 1

    		STAT Apoptosis Cancer
    STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a Kd value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer .
    STAT3-SH2 domain inhibitor 1
  • HY-P4998
    Chemotactic Domain of Elastin

    		Biochemical Assay Reagents Cancer
    Chemotactic Domain of Elastin is an elastin-derived peptide with chemotactic effects on certain tumor cells, such as M27 tumor cells. Chemotactic Domain of Elastin can be used in cancer research .
    Chemotactic Domain of Elastin
  • HY-P1195
    PDZ1 Domain inhibitor peptide

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide
  • HY-138283
    MR837
    1 Publications Verification

    		 Histone Methyltransferase Cancer
    MR837 is an inhibitor of NSD2-PWWP1. MR837 can bind with human nuclear receptor binding SET domain protein 2 (PWWP domain) .
    MR837
  • HY-P2516
    Tau Peptide (275-305) (Repeat 2 domain)

    		Tau Protein Neurological Disease
    Tau Peptide (275-305) (Repeat 2 domain) is the Alzheimer's tau fragment R2, corresponding to the second repeat unit of the microtubule-binding domain, which is believed to be pivotal to the biochemical properties of full tau protein .
    Tau Peptide (275-305) (Repeat 2 domain)
  • HY-P10108
    Hexokinase II VDAC binding domain peptide, cell-permeable

    Hxk2VBD peptide, cell-permeable

    		 Hexokinase Neurological Disease
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .
    Hexokinase II VDAC binding domain peptide, cell-permeable
  • HY-P9802
    Anti-Spike-RBD Single Domain mAb

    SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain Antibody

    		 SARS-CoV Infection
    Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .
    Anti-Spike-RBD Single Domain mAb
  • HY-P10521
    Apolipoprotein KV domain (67-77)

    		VEGFR Cancer
    Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .
    Apolipoprotein KV domain (67-77)
  • HY-P1195A
    PDZ1 Domain inhibitor peptide TFA

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide TFA
  • HY-P4924
    Tau Peptide (244-274) (Repeat 1 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (244-274) (Repeat 1 Domain) is aTau fragment.
    Tau Peptide (244-274) (Repeat 1 Domain)
  • HY-P4927
    Tau Peptide (245-274) (Repeat 1 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (245-274) (Repeat 1 Domain) is aTau fragment.
    Tau Peptide (245-274) (Repeat 1 Domain)
  • HY-P4966
    Tau Peptide (306-336) (Repeat 3 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (306-336) (Repeat 3 Domain) is aTau fragment.
    Tau Peptide (306-336) (Repeat 3 Domain)
  • HY-155019
    Anticancer agent 128

    		IAP Cancer
    Anticancer agent 128 (compound 1) is an IAP inhibitor that covalently targets the BIR3 domains of XIAP, cIAP1, and cIAP2. Anticancer agent 128 targets the BIR3 domains of XIAP, cIAP1, and cIAP2 with IC50s of 24.9 nM, 19.3 nM, and 10.3 nM, respectively .
    Anticancer agent 128
  • HY-141539
    SETDB1-TTD-IN-1

    		Histone Methyltransferase Cancer
    SETDB1-TTD-IN-1 is a potent, selective and endogenous binder competitive ligand of SET domain bifurcated protein 1 tandem tudor domain (SETDB1-TTD) that binds to TTD, with a Kd of 88 nM. SETDB1-TTD-IN-1 increases SETDB1 methyltransferase activity. SETDB1-TTD-IN-1 can be used for the research of biological functions and disease associations of SETDB1-TTD .
    SETDB1-TTD-IN-1
  • HY-155018
    Anticancer agent 127

    		IAP Cancer
    Anticancer agent 127 (142D6) is an IAP inhibitor that covalently targets the BIR3 domains of XIAP, cIAP1, and cIAP2. Anticancer agent 127 targets the BIR3 domains of XIAP, cIAP1, and cIAP2 with IC50s of 12 nM, 14 nM, and 9 nM, respectively. Anticancer agent 127 has anticancer effects .
    Anticancer agent 127
  • HY-141539A
    SETDB1-TTD-IN-1 TFA

    		Histone Methyltransferase Cancer
    SETDB1-TTD-IN-1 TFA is a potent, selective and endogenous binder competitive ligand of SET domain bifurcated protein 1 tandem tudor domain (SETDB1-TTD) that binds to TTD, with a Kd of 88 nM. SETDB1-TTD-IN-1 TFA increases SETDB1 methyltransferase activity. SETDB1-TTD-IN-1 TFA can be used for the research of biological functions and disease associations of SETDB1-TTD .
    SETDB1-TTD-IN-1 TFA
  • HY-P99562
    Tidutamab

    XmAb-18087

    		 CD3 Cancer
    Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
    Tidutamab
  • HY-114207
    VinSpinIn

    		Epigenetic Reader Domain Others
    VinSpinIn is a Spindlin1 inhibitor (KD: 9.9 nM for SPIN149-262). VinSpinIn is a chemical probe for tudor domain of Spindlin1. VinSpinIn can be used to study chromatin function .
    VinSpinIn
  • HY-P99852
    Dilpacimab

    ABT165; PR1283233

    		 VEGFR Cancer
    Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer .
    Dilpacimab
  • HY-13956S
    Pioglitazone-d4

    U 72107-d4

    		 PPAR Ferroptosis Metabolic Disease Cancer
    Pioglitazone-d4 is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1].
    Pioglitazone-d4
  • HY-117570
    KSC-34

    		PDI Neurological Disease
    KSC-34, a covalent modifier of protein disulfide isomerase A1 (PDIA1), is also a selective and potent a-site inhibitor of PDIA1 with an IC50 of 3.5 μM. KSC-34 displays a 30-fold selectivity for a domain over a′ domain and displays high selectivity for PDIA1 in complex proteomes with minimal engagement of other members of the PDI family . KSC-34 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    KSC-34
  • HY-15098
    Apoptozole
    5+ Cited Publications

    Apoptosis Activator VII

    		 HSP Apoptosis Cancer
    Apoptozole (Apoptosis Activator VII) is an inhibitor of the ATPase domain of Hsc70 and Hsp70, with Kds of 0.21 and 0.14 μM, respectively, and can induce apoptosis.
    Apoptozole
  • HY-150619
    KDM4-IN-4

    		Histone Demethylase Cancer
    KDM4-IN-4 (compound 47) is a potent histone lysine demethylase 4 (KDM4) inhibitor with a modest affinity binding to ~80 μM for KDM4A-Tudor domain. KDM4-IN-4 can inhibit H3K4Me3 binding to the Tudor domain in cells with an EC50 value of 105 μM. KDM4-IN-4 can be used for researching anticancer .
    KDM4-IN-4
  • HY-P4972
    Tau Peptide (45-73) (Exon 2/Insert 1 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (45-73) (Exon 2/Insert 1 Domain) is aTau fragment.
    Tau Peptide (45-73) (Exon 2/Insert 1 Domain)
  • HY-P4977
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain) is aTau fragment.
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain)
  • HY-141799
    Dimethyl-F-OICR-9429-COOH

    		Ligands for Target Protein for PROTAC Cancer
    Dimethyl-F-OICR-9429-COOH a ligand for WD40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1 intermediate 19. Dimethyl-F-OICR-9429-COOH can be used in the synthesis of PROTACs .
    Dimethyl-F-OICR-9429-COOH
  • HY-153992
    STAT6-IN-3

    		STAT Inflammation/Immunology
    STAT6-IN-3 (Compound 18a) is a STAT6 inhibitor (IC50= 44 nM). STAT6-IN-3 targets the Src Homology 2 (SH2) domain of STAT6. STAT6-IN-3 can be used for research of inflammation such as asthma .
    STAT6-IN-3
  • HY-150400
    XF056-132 free base

    		PROTACs Histone Methyltransferase Cancer
    XF056-132 free base is a potent WDR5 (WD40 repeat domain protein 5) PROTAC degrader .
    XF056-132 free base
  • HY-139287
    M1002
    1 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .
    M1002
  • HY-P10566
    BCOR(498-514), biotinylated

    		BCL6 Cancer
    BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an KD value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells .
    BCOR(498-514), biotinylated
  • HY-149935
    OICR-8268

    		Ligands for E3 Ligase Cancer
    OICR-8268 is a reversible DCAF1 ligand that binds to the DCAF1 WDR domain with a Kd of 38 nM. OICR-8268 can enable the development of DCAF1-based PROTACs .
    OICR-8268
  • HY-161916
    Polθ-IN-4

    		DNA/RNA Synthesis Cancer
    Polθ-IN-4 (Example 1) is a DNA polymerase theta (Polθ) inhibitor that inhibits Polθ activity by targeting its ATP-dependent helicase domain. Polθ-IN-4 can be utilized in cancer research .
    Polθ-IN-4
  • HY-P99104
    Plutavimab

    COVI-AMG; STI-2020

    		 SARS-CoV Infection
    Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
    Plutavimab
  • HY-157332
    WDR5-IN-7

    		Histone Methyltransferase Cancer
    WDR5-IN-7 (Compound 22) is an orally bioavailable benzoxazepinone-based WD repeat domain 5 (WDR5) inhibitor. WDR5-IN-7 can be used for the research of anti-cancer .
    WDR5-IN-7
  • HY-162175
    TAMRA-isoADPr

    		Fluorescent Dye Cancer
    TAMRA-isoADPr is a fluorescently tagged iso-ADP-ribose tracer compound. TAMRA-isoADPr is a high-affinity tracer for the RNF146 WWE domain with a Kd of 45.2 nM .
    TAMRA-isoADPr
  • HY-18377
    Bioymifi

    DR5 Activator

    		 TNF Receptor Apoptosis Cancer
    Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .
    Bioymifi
  • HY-19820A
    NSC45586 sodium

    		Akt Ser/Thr Protease Neurological Disease Cancer
    NSC45586 sodium is an inhibitor of pleckstrin homology domain and leucine-rich repeat protein phosphatase (PHLPP). NSC45586 sodium targets the PP2C phosphatase domain in PHLPP1 and PHLPP2. NSC45586 sodium can activate AKT in neurons .
    NSC45586 sodium
  • HY-19820
    NSC45586

    		Akt Ser/Thr Protease Neurological Disease Cancer
    NSC45586 is an inhibitor of pleckstrin homology domain and leucine-rich repeat protein phosphatase (PHLPP). NSC45586 targets the PP2C phosphatase domain in PHLPP1 and PHLPP2. NSC45586 can activate AKT in neurons .
    NSC45586
  • HY-115383
    Roflupram
    1 Publications Verification

    		 Phosphodiesterase (PDE) Neurological Disease Inflammation/Immunology
    Roflupram is a selective, orally active and brain-penetrant PDE4 inhibitor, with an IC50 of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors .
    Roflupram
  • HY-141798
    OICR-9429-N-C2-NH2

    		Ligands for Target Protein for PROTAC Cancer
    OICR-9429-N-C2-NH2 is a ligand for Wd40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1, intermediate 2. OICR-9429-N-C2-NH2 can be used in the synthesis of PROTACs .
    OICR-9429-N-C2-NH2
  • HY-P10316
    CaMKI(299-320)

    Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain

    		 CaMK Others
    CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca 2+-CAM (Kd≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .
    CaMKI(299-320)
  • HY-13956
    Pioglitazone
    25+ Cited Publications

    U 72107

    		 PPAR Ferroptosis Metabolic Disease Cancer
    Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .
    Pioglitazone
  • HY-13956B
    Pioglitazone potassium

    U 72107 potassium

    		 PPAR Ferroptosis Metabolic Disease Cancer
    Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research .
    Pioglitazone potassium
  • HY-150047
    BK60106

    		Apoptosis Cancer
    BK60106 is a CD99 inhibitor that directly binds to the extracellular domain of CD99. BK60106 selectively kill Ewing sarcoma (ES) cells. BK60106 induces apoptosis in ES cells with less DNA damage .
    BK60106
  • HY-153242
    GSK217

    		Epigenetic Reader Domain Inflammation/Immunology
    GSK217 is a potent, selective, and highly soluble bromo and extraterminal domain (BET) second bromodomain (BD2) inhibitor. GSK217 can be used for the research of oncology and immune inflammation research .
    GSK217
  • HY-P4933
    Tau Peptide (255-314) (Repeat 2 Domain) (human)

    		Tau Protein Others
    Tau Peptide (255-314) (Repeat 2 Domain) (human) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
    Tau Peptide (255-314) (Repeat 2 Domain) (human)
  • HY-P99833
    Cosibelimab

    CK-301; TG-1501

    		 PD-1/PD-L1 Cancer
    Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 + cell lines, including lymphoma cells .
    Cosibelimab
  • HY-116501
    VPC-14449

    		Androgen Receptor Cancer
    VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer .
    VPC-14449
  • HY-131346
    HIF-PHD-IN-1

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    HIF-PHD-IN-1 is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD), with an IC50 of 54 nM for hHIF-PHD2. HIF-PHD-IN-1 is promising therapeutic agents for renal anemia .
    HIF-PHD-IN-1
  • HY-147088
    TEAD-IN-2

    		YAP Cancer
    TEAD-IN-2 is a novel, orally active inhibitor of transcriptional enhancer associate domain (TEAD) and modulates TEAD by ubiquitination and/or degradation by compounds. TEAD-IN-2 can be used for the research of a variety of diseases, disorders or conditions associated with TEAD .
    TEAD-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: